Search results for Astegolimab

Astegolimab Biosimilar – Anti-IL1RL1 mAb – Research Grade, ProteoGenix, PX-TA1577

Description of Astegolimab Biosimilar - Anti-IL1RL1 mAb - Research Grade Introduction Astegolimab Biosimilar, also known as Anti-IL1RL1 mAb, is a novel therapeutic antibody that has shown promising results in the treatment of various inflammatory diseases. This biosimilar is a research-grade version of the original Astegolimab, which is a monoclonal antibody designed to specifically target the interleukin-1 receptor like 1 (IL1RL1) protein. In this article, we will delve into the structure, activity, and potential applications of Astegolimab Biosimilar in the field of immunotherapy. Structure of Astegolimab Biosimilar Astegolimab Biosimilar is a humanized IgG1 monoclonal antibody, which means it is composed of human antibody sequences with a small portion of non-human antibody sequences. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains contain four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL) and one variable domain (VL). The variable domains of Astegolimab Biosimilar are responsible for binding to the IL1RL1 protein, while the constant domains play a role in effector functions. Activity of Astegolimab Biosimilar The main target of Astegolimab Biosimilar is the IL1RL1 protein, also known as the interleukin-33 receptor (IL-33R). This protein is a member of the interleukin-1 receptor family and is expressed on various immune cells, including T cells, B cells, and dendritic cells. IL1RL1 is involved in the regulation of immune responses and has been implicated in the pathogenesis of several inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Astegolimab Biosimilar works by binding to IL1RL1 and blocking its interaction with its ligand, IL-33. This prevents the activation of downstream signaling pathways, leading to a decrease in the production of pro-inflammatory cytokines and chemokines. As a result, Astegolimab Biosimilar helps to reduce inflammation and alleviate symptoms associated with inflammatory diseases. Potential Applications of Astegolimab Biosimilar Based on its mechanism of action, Astegolimab Biosimilar has the potential to be used in the treatment of various inflammatory diseases. Some of the conditions that may benefit from this biosimilar include: – Asthma: IL1RL1 has been shown to play a role in the development of asthma, and blocking its activity with Astegolimab Biosimilar may help to reduce airway inflammation and improve lung function. – Rheumatoid arthritis (RA): IL1RL1 has also been implicated in the pathogenesis of RA, and targeting this protein with Astegolimab Biosimilar may help to reduce joint inflammation and improve symptoms. – Inflammatory bowel disease (IBD): Studies have shown that IL1RL1 is upregulated in patients with IBD, and blocking its activity with Astegolimab Biosimilar may help to reduce intestinal inflammation and improve disease activity. – Psoriasis: IL1RL1 has been found to be involved in the development of psoriasis, and Astegolimab Biosimilar may have a role in reducing skin inflammation and improving symptoms in patients with this condition. Conclusion In summary, Astegolimab Biosimilar is a promising therapeutic antibody that specifically targets the IL1RL1 protein. Its unique structure and mechanism of action make it a potential treatment option for various inflammatory diseases. Further research and clinical trials are needed to fully understand the efficacy and safety of this biosimilar, but it holds great potential in the field of immunotherapy.

Astegolimab, Kyinno, KB-1703

Astegolimab, Abbexa, abx831536

Astegolimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL1RL1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Astegolimab ELISA Kit, ProteoGenix, KPTX235

Description of Astegolimab ELISA Kit Introduction Astegolimab is a promising monoclonal antibody that has shown great potential as a therapeutic target for various inflammatory and autoimmune diseases. This antibody has been extensively studied and its activity has been well documented. In this article, we will provide a comprehensive scientific description of the Astegolimab ELISA Kit, including its structure, activity, and potential applications. Structure of Astegolimab Astegolimab is a humanized IgG1 monoclonal antibody that specifically targets the interleukin-33 (IL-33) receptor, also known as ST2. The antibody is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to the IL-33 receptor, while the constant regions determine the effector functions of the antibody. Activity of Astegolimab The main activity of Astegolimab is its ability to block the interaction between IL-33 and its receptor, ST2. IL-33 is a pro-inflammatory cytokine that is involved in various inflammatory and autoimmune diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. By blocking the IL-33/ST2 pathway, Astegolimab can effectively reduce the production of pro-inflammatory cytokines and alleviate the symptoms of these diseases. In addition to its anti-inflammatory activity, Astegolimab also has other effector functions that contribute to its therapeutic potential. These include antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC is the process by which immune cells, such as natural killer cells, are activated to kill target cells that are coated with antibodies. CDC, on the other hand, involves the activation of the complement system, which leads to the destruction of target cells. These effector functions enhance the efficacy of Astegolimab in treating diseases. Application of Astegolimab ELISA Kit The Astegolimab ELISA Kit is a valuable tool for measuring the levels of Astegolimab in biological samples. This kit utilizes a sandwich ELISA method, in which the antibody is immobilized on a solid surface and then used to capture Astegolimab from the sample. The captured antibody is then detected using a secondary antibody that is conjugated with an enzyme. The enzyme catalyzes a colorimetric reaction, which can be quantified using a spectrophotometer. The Astegolimab ELISA Kit has numerous applications in both research and clinical settings. In research, the kit can be used to determine the pharmacokinetics of Astegolimab, such as its half-life and clearance rate, in animal models and human subjects. It can also be used to monitor the levels of Astegolimab in patients undergoing treatment, which can help in dose optimization and predicting response to therapy. In the clinical setting, the Astegolimab ELISA Kit can be used for patient screening and monitoring during treatment. It can also be used to assess the efficacy of Astegolimab in clinical trials and to determine the appropriate dosage for individual patients. Additionally, the kit can be used to measure the levels of Astegolimab in different body fluids, such as blood, serum, and synovial fluid, which can provide valuable insights into the distribution and tissue penetration of the antibody. Conclusion In conclusion, Astegolimab is a promising therapeutic target for various inflammatory and autoimmune diseases. The Astegolimab ELISA Kit is a valuable tool for measuring the levels of Astegolimab in biological samples, which can aid in research and clinical applications. With its specific targeting of the IL-33/ST2 pathway and its effector functions, Astegolimab has the potential to provide a safe and effective treatment option for patients suffering from these debilitating diseases.

Astegolimab ELISA Kit, Abbexa, abx395124

Astegolimab ELISA Kit is a quantitative ELISA kit for detection of Astegolimab.Astegolimab, a human IgG2mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients with elevated blood eosinophils (type 2-high), but limited options are available for patients with low blood eosinophils (type 2-low).

Astegolimab Biosimilar - Research Grade, ichor.bio, ICH5356

Research Grade Astegolimab (MX139016), abinScience, MX139016